Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer - Wikidata - awgldk - TriplyDB

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

http://www.wikidata.org/entity/Q33641143

about

Translational research in diagnosis and management of soft tissue tumours Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in mice Molecular imaging: 18F-FDG PET and a whole lot more.Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data Imaging and 'omic' methods for the molecular diagnosis of cancer.Ultrasound targeted apoptosis imaging in monitoring early tumor response of trastuzumab in a murine tumor xenograft model of her-2-positive breast cancer(1.).In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts.[18F]FLT PET for non-invasive assessment of tumor sensitivity to chemotherapy: studies with experimental chemotherapy TP202377 in human cancer xenografts in mice [18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in mice.Limits of [18F]-FLT PET as a biomarker of proliferation in oncology Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer.Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PET Development of radiotracers for oncology--the interface with pharmacology 3'-Deoxy-3'-[18F]-Fluorothymidine PET imaging reflects PI3K-mTOR-mediated pro-survival response to targeted therapy in colorectal cancer.Assessment of tumor response to tyrosine kinase inhibitors Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.Tenascin-C: Exploitation and collateral damage in cancer management [(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients Towards detecting the HER-2 receptor and metabolic changes induced by HER-2-targeted therapies using medical imaging.Comparative functional evaluation of immunocompetent mouse breast cancer models established from PyMT-tumors using small animal PET with [(18)F]FDG and [(18)F]FLT Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.High-yielding, automated production of 3'-deoxy-3'-[(18)F]fluorothymidine using a modified Bioscan Coincidence FDG reaction module.Assessing the reproducibility of dynamic contrast enhanced magnetic resonance imaging in a murine model of breast cancer.Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells.Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer.A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells.Phosphatidylserine targeting for diagnosis and treatment of human diseases.Molecular imaging metrics to evaluate response to preclinical therapeutic regimens.Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.NEAR-INFRARED DYES: Probe Development and Applications in Optical Molecular Imaging.Preclinical Applications of 3'-Deoxy-3'-[18F]Fluorothymidine in Oncology - A Systematic Review.Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.Response to trastuzumab by HER2 expressing breast tumour xenografts is accompanied by decreased Hexokinase II, glut1 and [18F]-FDG incorporation and changes in 31P-NMR-detectable phosphomonoesters.

P2860

Q26748651-D572E112-E819-4D30-BB1C-F90A9ED8B5C7 Q26778463-1204F349-CD39-4DAC-8C5C-DB634AA1FDED Q28475583-694529EC-8F83-4FFA-AC88-A99577636C0C Q30482989-F131595B-8261-4CAE-A404-C72BD824FEAA Q30564565-2613BEBF-37AB-4661-BD86-5CE8D4CC79FF Q33577268-3E642703-AFDC-4B24-8787-A9C3FF10B5FC Q33912300-81B3B33A-0EDA-4592-83D5-178B6B0ECD9A Q33915825-63DB5228-E2A1-4EC9-AAC9-C3FDF89CEF1C Q34505642-283AB227-9906-40CF-B4C6-EC88C74C5B17 Q34645445-837C6D60-0CB1-436D-8B83-CD14C6260027 Q34648592-237076F6-ADAB-4B36-8B2E-309581055BA6 Q35031049-57D52180-D92F-420E-9C14-191560606303 Q35065961-A5DD7CA1-B429-4202-97F7-C89C6FBACB5B Q35081130-D239BFC4-5C20-4410-9863-082969073942 Q35195500-29AD92C6-CBE7-4628-938E-94502F0E9F7A Q35271098-18E36C16-A693-4756-B3AE-C4EDF74F8064 Q35558589-B5BDF68D-2D9F-405D-9B8F-B659521B57ED Q35558962-FD0E5AEF-9426-4CC0-9EF5-AD0E62882482 Q35577959-5188C306-4B4E-454B-A083-1CFC66E7A7D4 Q35855226-A2B4BEC2-503B-4BC6-B4E4-ACDCDF481E68 Q36239959-F1C5E68C-E484-4E5C-A02E-4E8F2B3E405F Q36324211-8AED3115-0DE0-43C5-8F23-FF4506832BDC Q36338316-A93A59F6-15D6-4A41-BED7-39D21875A817 Q36339722-5C6E4F17-D963-4C92-9FD0-3F3C5E0C0100 Q36533822-D59CE06F-B27E-41DD-B35A-9A7483D62B87 Q36557319-5D2C08C0-3163-4577-B99B-79D03958905E Q36665931-D775EB68-CC2E-4B3F-88A6-56FACE154E66 Q36902928-23AA7B32-682C-428A-8836-2E15CEB96854 Q37088411-B4F286A6-2458-4D09-9869-54ACFC48DAA2 Q37241740-3004FBC0-8015-43D8-AC59-9C4C7FD14BA1 Q37456176-A146D102-307A-4954-BF0E-7C2879CDA4B1 Q37559704-54AB2EB9-1DED-42F4-A6B1-2A64541D595E Q37707164-31B89A98-4104-49F8-B6C1-29815017CB4C Q37741860-973D5421-4035-406F-8C93-D5C451875F10 Q37825149-8366C0E2-E602-4F40-84F3-531A0B6B3167 Q37871191-2B28F47A-FFDB-4516-B79A-ACC68E88B8D1 Q37913039-E73ED4FB-0CE8-41B9-B715-ADE85FCE8AF4 Q38775709-2ECA94A6-A706-4377-B848-ADDAC533D6D5 Q39024453-4D102829-403A-4706-B7DA-A7840969508D Q39239280-CDC33C83-8793-4322-ADED-4F32B0C99B40

P2860

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer

http://www.wikidata.org/entity/Q33641143

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Imaging biomarkers predict res ...... inical models of breast cancer

@ast

Imaging biomarkers predict res ...... inical models of breast cancer

@en

type

label

Imaging biomarkers predict res ...... inical models of breast cancer

@ast

Imaging biomarkers predict res ...... inical models of breast cancer

@en

prefLabel

Imaging biomarkers predict res ...... inical models of breast cancer

@ast

Imaging biomarkers predict res ...... inical models of breast cancer

@en

P1433

Q33641143-5660FFC7-7C07-46B1-99BF-1A211F67FE92

P1476

Q33641143-F9B648CF-2257-4493-9D34-892212FF4526

P2093

Q33641143-02102E93-C35E-4F74-9E62-4F64FBBD1F4E

Q33641143-06ACA022-9010-4921-87B7-2C6A456DAB36

Q33641143-139676FA-1C9C-4A32-A1F4-729ACA4E3BC4

Q33641143-2239E570-5B65-4011-B83E-C7EDCDBFB970

Q33641143-270B474F-C958-4B18-9775-09FFC7612D56

Q33641143-70C952DF-196A-4B49-9457-C9F72529517F

Q33641143-9B6FA6DC-35D3-4BCB-983D-4D84E7F6DB1D

Q33641143-C2DEC81F-FB21-4E9F-BC4C-D7204F78A483

Q33641143-CBF65F77-B54C-4372-BE5E-F79DA9C36F79

Q33641143-D6F4EEF4-FA40-424D-8744-116A5B1019A7

P2860

Q33641143-0488B926-2610-4E1E-832B-E558FBD1E54A

Q33641143-090E8BB9-17FC-4572-8673-0B9CAAA4E596

Q33641143-21040D9C-5EE8-4C3E-9CB6-2471C3E73D52

Q33641143-39E2C22D-FD44-4709-BAED-6FF0605769E8

Q33641143-3E3492A1-BEEC-4585-B84E-E1B9802EDB48

Q33641143-4D7DE18A-AC61-41F9-90A6-CB62DB3D2339

Q33641143-4DCA87E3-4E80-4A4C-B697-22970ECEC414

Q33641143-51910B19-7676-4C78-B1FC-32726D3AA1CF

Q33641143-5321C1C9-7475-4198-944C-D57BA13E0EC0

Q33641143-56188CB1-E320-4FA8-A65B-8A135D0FD955

P304

Q33641143-A784605D-EF20-483F-9B80-99836D1F48C1

P31

Q33641143-BBD2976E-995E-4D5B-94A0-57919770B59B

P356

Q33641143-1A88635A-6331-49F1-AE2C-0F85B7595068

P407

Q33641143-B743FBFB-C303-4338-9982-7CC2846D8310

P433

Q33641143-259B559B-D823-4737-AADB-AF127448522C

P478

Q33641143-CFF9DD18-A546-4236-9958-0FB6EB1EB3F2

P577

Q33641143-974AAEDB-FACB-4A5E-B094-16C49D6DDD63

P698

Q33641143-C8C51A5B-30D3-4425-8055-38DB67A0341F

P921

Q33641143-EA9D23C2-743C-44E7-8998-1D677A451B37

P932

Q33641143-779C045B-8BD8-4E26-864E-5BD20B15EE58

P356

1078-0432.CCR-08-2635

P1433

Clinical Cancer Research

P1476

Imaging biomarkers predict res ...... inical models of breast cancer

@en

P2093

Carlos L Arteaga

http://www.w3.org/2001/XMLSchema#string

Chirayu Shah

http://www.w3.org/2001/XMLSchema#string

Donald D Nolting

http://www.w3.org/2001/XMLSchema#string

Eliot T McKinley

http://www.w3.org/2001/XMLSchema#string

H Charles Manning

http://www.w3.org/2001/XMLSchema#string

Jason R Buck

http://www.w3.org/2001/XMLSchema#string

John C Gore

http://www.w3.org/2001/XMLSchema#string

M Sib Ansari

http://www.w3.org/2001/XMLSchema#string

Maria Graciela Olivares

http://www.w3.org/2001/XMLSchema#string

Ping Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Humanization of an anti-p185HER2 antibody for human cancer therapy

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics.

Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.

Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts.

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers.

P304

4712-4721

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-2635

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19584166

http://www.w3.org/2001/XMLSchema#string

P921

P932

2819132

http://www.w3.org/2001/XMLSchema#string